What tesofensine dose do the sources give?
| Form | Tesofensine strength | Where it appears |
|---|---|---|
| Trial tablet | 0.5 mg, two tablets for a 1 mg dose2 | NCT03286829 comparator arm, single dose, in a parallel-arm study of 60 healthy male subjects |
| Fixed-dose tablet with metoprolol (Tesomet) | 0.2 mg (low, with 5 mg IR and 20 mg ER metoprolol) and 1 mg (high, with 20 mg IR and 80 mg ER metoprolol)2 | NCT03286829, single dose |
| Supplement capsule | 500 μg labelled per capsule; 483 μg measured by product analysis3 | Urine study, single dose, six healthy volunteers |
In the 24-week phase 2 trial of 203 obese patients on an energy restricted diet (Astrup 2008, Lancet), tesofensine 0.25 mg (n=52), 0.5 mg (n=50), or 1.0 mg (n=49), or placebo (n=52) was given once daily, and a DailyMed search returned no tesofensine label.1
Strengths and how it is supplied
The table is set at the top of the page
No label or maker's leaflet strength is in the sources, so the strengths above come from trial tablets and one supplement. Where the sources give a form, it is oral: tablets in four trials, oral dosing in the pooled analysis, and a capsule in the urine study.452673
Doses, schedules and length in trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Astrup 2008 (Lancet), obesity1 | 0.25 mg (n=52), 0.5 mg (n=50), or 1.0 mg (n=49), or placebo (n=52) once daily, with an energy restricted diet | 203 randomised, 161 completed | 24 weeks |
| ADVANS (Rascol 2008), advanced Parkinson disease48 | 0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg once daily, oral tablets, or placebo | 254 enrolled | 14 weeks |
| Astrup 2008 pooled analysis of four trials, Parkinson or Alzheimer disease7 | 0.125, 0.25, 0.5 or 1.0 mg once daily, oral, or placebo, without any weight loss program | 740 on tesofensine, 228 on placebo | 14 weeks |
| Gilbert 2012, appetite9 | Part 1: 0.25, 0.5 or 1.0 mg, or placebo; Part 2 (open label, single group): 0.5 or 1.0 mg | 158 in Part 1, 113 in Part 2 | 24 weeks each part, with a 12 ± 3 week drug-free period between |
| Huynh 2022 (Tesomet, NCT03845075), hypothalamic obesity1011 | Tesomet (0.5 mg tesofensine/50 mg metoprolol) or placebo, with diet/lifestyle counselling | 21 adults, eighteen completed | daily for 24 weeks |
| NCT02737891, type 2 diabetes5 | 0.5 mg tesofensine + metoprolol 100 mg, oral tablets, or matching placebo | 60 enrolled | ninety (90) days |
| NCT03149445, Prader-Willi syndrome12 | Adults 0.5 mg tesofensine/50 mg metoprolol; adolescents 0.125 mg tesofensine/25 mg metoprolol; or placebo; once daily | 18 enrolled (9 adults, 9 adolescents) | 91 days |
In NCT03845075, the Tesomet trial above, the active arm got 0.5 mg tesofensine/50 mg metoprolol once daily for 24 weeks, and everyone still in the study was offered the same for a further 24 weeks open label, including those switched from placebo.11 In NCT03149445, adolescents could go on to two 12-week open-label extensions; 8 entered the first (OLE I), on 0.125 mg tesofensine/25 mg metoprolol (Tesomet) once daily for 12 weeks.12 In the second (OLE II), 6 continued: 5 started on 0.25 mg tesofensine/25 mg metoprolol and the other on 0.125 mg tesofensine/25 mg metoprolol, each once daily for 12 weeks.12
In the phase 1 heart-rate study NCT03488719 of 37 otherwise healthy adults with overweight or obesity, the 0.25 mg cohort got tesofensine once daily for 23 days, with a 1.0 mg loading dose for the first 3 days, plus a single dose of 25 mg, 50 mg or 100 mg metoprolol extended release in random order on Day 15, Day 18 and Day 21.610 The 0.50 mg cohort had a 2.0 mg loading dose for the first 3 days, and the 0.75 mg cohort (0.25 mg + 0.50 mg) a 2.0 mg loading dose (4 tablets of 0.50 mg) for the first 5 days.6 The registry entry says the study was temporarily halted on 22 November 2018 after 2 subjects in dose cohort 2 had prolonged tachycardia (over 120 beats per minute lasting for 30 min), and the sponsor, Saniona, ended it on 20 February 2019, having judged the results from completed participants sufficiently robust.6 No label dose-stepping is in the sources, and the obesity trial reports in the sources give no titration schedule.
Label and regulatory status
An FDA warning letter to Darmerica, LLC, dated December 08, 2025, lists tesofensine among active ingredients ineligible for use in human drug compounding under section 503A, and says the labelling of these drugs fails to bear adequate directions for use.13
Powder, mixing, syringe marks and storage
Searches of DailyMed, ClinicalTrials.gov and PubMed returned no powder, drops, liquid or vial form of tesofensine. With no injectable concentration, there is no tesofensine figure to turn into a volume or syringe mark. No storage statement for tesofensine, before or after mixing, is in the sources.
Frequently asked questions
Has the 2008 obesity trial been questioned?
References
- PubMed. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. 2008. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT03286829: Study to Investigate the Pharmacokinetic Profile. 2020. clinicaltrials.gov
- Drug Test Anal. Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. 2026. pmc.ncbi.nlm.nih.gov
- PubMed. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. 2008. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT02737891: Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus. 2020. clinicaltrials.gov
- ClinicalTrials.gov. NCT03488719: A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate. 2024. clinicaltrials.gov
- PubMed. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. 2008. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT00148512: A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations. 2005. clinicaltrials.gov
- PubMed. The effect of tesofensine on appetite sensations. 2012. pubmed.ncbi.nlm.nih.gov
- Eur J Endocrinol. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. 2022. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT03845075: 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO). 2024. clinicaltrials.gov
- ClinicalTrials.gov. NCT03149445: Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS). 2024. clinicaltrials.gov
- US FDA. Darmerica, LLC - 716152 - 12/08/2025. fda.gov
- PubMed. Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. 2013. pubmed.ncbi.nlm.nih.gov